Navigation Links
Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy'

Critique of Industry-Funded Immune Globulin Study Uncovers Sample Manipulation, Design Flaws

NIXA, Mo., June 26, 2007 /PRNewswire-USNewswire/ -- An analysis released today critically examined a recent industry-sponsored study ruling out a link between autism and Rh immune globulin (RhIg) injections, some of which contained the mercury-based preservative thimerosal. Besides extensive design flaws, the analysis uncovered manipulation of the study sample, so that earlier data revealing a positive autism-RhIg association was concealed.

"This study is just another example of the pharmaceutical industry's corruption of research to suit its own purposes," according to National Autism Association president and parent Wendy Fournier. "They back the study designs that give the desired results of no harm."

Johnson & Johnson, parent company of Ortho Clinical Diagnostics, which manufactures the once mercury-sterilized RhIg shot RhoGAM, funded the study. It was published in the May 2007 American Journal of Medical Genetics (AJMG) by Judith H. Miles and T. Nicole Takahashi of the University of Missouri.

A University press release entitled, "Study Finds No Link Between Autism and Thimerosal in Vaccines" suggested deliberate deception as immune globulins are not vaccines. J & J's involvement in the study was not disclosed in the press release, and J&J's role as the parent of Ortho and the largest manufacturer of mercury-containing RhIg were not communicated in the published paper. Dr. Miles has served as a paid consultant in autism-related litigation involving RhIg, which was also not divulged.

The critical analysis, conducted by the nonprofit research organization SafeMinds, examined earlier data from a 2005 poster presentation of the Miles and Takahashi research. They found that between the 2005 and 2007 versions, the control groups changed and major portions of the original autism samp le were removed. Calculations based on the original data indicate that children with autism "were 71% more likely to have been exposed to RhIg in utero than their non-ASD siblings," according to the SafeMinds analysis.

NAA's Fournier points out that the RhIg study fits a recurring pattern for thimerosal research with drug company/researcher ties. Manipulation of data to reach a desired conclusion was seen in CDC studies conducted in 2000 showing a relationship between thimerosal-containing vaccines and a range of adverse neurological effects including autism. The data was manipulated to lower the relative risk factor before publication in the journal Pediatrics in 2004. Lead investigator Dr. Thomas Verstraeten left the CDC to work for vaccine maker Glaxo-Smith-Kline in 2001 while the data alterations were ongoing, but his employment was not disclosed by the journal. Likewise, Dr. Michael Pichichero, an Eli Lilly-funded researcher and holder of numerous vaccine patents, tried to clear thimerosal as harmful by conducting a blood mercury evaluation after infant vaccination which missed peak blood levels, had a sample size too small to detect susceptible subgroups, and failed to address implications of the findings for long term mercury deposition in the brain. His industry ties were not disclosed by the journal, The Lancet.

"While this latest RhIg effort is the best science drug money can buy," points out Ms. Fournier, "NAA feels that the public and families with autism deserve better quality studies. This is a critical product safety issue." RhIg is given to approximately 15% of all pregnant women.

To read the entire analysis, go to http://www.safeminds.org. For more about autism, visit http://www.nationalautism.org.

Contacts:

Rita Shreffler (Nixa, MO) 401-632-6452

Wendy Fournier (Portsmouth, RI) 401-632-7523< /p>

CONTACT: Rita Shreffler, Nixa, MO, +1-401-632-6452, or Wendy Fournier,Portsmouth, RI, +1-401-632-7523, both of National Autism Association

Web site: http://www.nationalautism.org/http://www.safeminds.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
3. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Myriad Genetics Presents Tumor Origin Technology at AACR
6. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 --> ... Gas), and Spectroscopy Market by Industry (Oil & Gas, Petrochemical, ... Paper, Metal & Mining, and Others), And Geography - ... market is expected to grow to USD 3.9 Billion ... 2015 and 2020. Browse 82 market data ...
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology:
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
(Date:2/10/2016)... ... 2016 , ... Early this week, Team Iconic at J. Walter Thompson and ... the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa ... product, through activities that focus on better farming, better lives and better cocoa. In ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... Inc. , a full-service health care communications company offering education, research and ... resource for practitioners and specialists working in infectious diseases. , As the ...
Breaking Medicine News(10 mins):